Dr. Andy Moye is Chief Executive Officer and board member for Paige, a company with a vision to transform cancer diagnostics through AI.  Paige was spun out of Memorial Sloan Kettering Cancer Center in 2018 and during his time with the company, Moye’s accomplishments include the U.S. launch of Paige Prostate, the first and only AI-based pathology product to receive FDA approval for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies.  Andy has always been driven to serve others, and began his career as a Flight Officer in the US Navy, flying missions in Iraq and the Middle East.   Dr. Moye is also passionate about making a difference in the fight against cancer, and has worked across the molecular diagnostics, biotechnology, and life sciences industries at the forefront of precision medicine in oncology.  Notably, he served as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, delivering significant growth in both markets for emerging businesses.   He has also served in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio.   Andy Moye’s educational career includes a Bachelor of Science in Physiology from the University of Arizona, an MBA from the University of Florida, and a PhD in Health Economics.  Andy has won numerous awards for leadership including Top 25 Healthcare Technology Leaders in Dallas and was recently named to the JPMorgan Chase 2024 CEOcircle cohort for Bunker Labs, an executive program for military veteran CEOs and entrepreneurs.